Urologix signs deal to sell Prostiva RF therapy system for BPH

Urologix ($ULGX) has inked an exclusive worldwide license for the Prostiva RF therapy system from Medtronic ($MDT). The system is a transurethral needle ablation device that is 510(k) cleared for the treatment of BPH. The license agreement is for a 10-year term and includes the rights to manufacture and market the Prostiva product line for an upfront license fee and ongoing royalties. Urologix release